Importantly, while the indolizidine moiety prefers a cis-fused conformation, 2 trans-fused quinolizidines are preferred. 3 The stereochemistry of the pyramidal nitrogen at the ring junction may accounts for some important differences between the bioactivities of these subfamilies of alkaloids. 7 and exhibited IC 50 in the low nanomolar range against twelve cancer cell lines. 8 Other structure-activity relationships (SAR) studies have also revealed that phenanthroquinolizidines are more potent anti-tumor agents than phenanthroindolizidine alkaloids. 9 Encouraged by the discovery of natural phenanthroquinolizidines with important biological properties, some elegant asymmetric syntheses have been recently reported for these compounds. 10, 11 It is reported that racemic 7-methoxycryptopleurine 12 displays potent anti-inflamatory activity, 13 as well as remarkable cytotoxicity at submicromolar concentrations against different human cancer cell lines. 3a,14 In addition, the group of Wang has found that both enantiomers of the title compound show significant antiviral activity (in vitro and in vivo) against tobacco mosaic virus (TMV), being the R-enantiomer the most active one. 15 Moreover, the same group has recently reported that different salts of the title compound, or derivatives where the methyl groups were removed, gave excellent anti TMV activity. 16 To our best knowledge, the only enantioselective synthesis reported for this promising bioactive compound takes place with partial racemization over a
Parham-type cycloacylation.
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Prompted by the unique biological activities of 7-methoxycryptopleurine and the lack of efficient protocols for its preparation with high enantiomeric purity, we report herein two alternative protocols for the synthesis of enantioenriched (R)-and (S)-7-methoxycryptopleurine. Both synthetic strategies relied on a late Pictet-Spengler formation of ring D 18 and the formation of ring E was examined using either hydroformylation or ring-closing metathesis (RCM) 19 as the key steps, from the same chiral homoallylic sulfinamine intermediate 20 (Scheme 1). Since we have previously shown that these chiral intermediates can be efficiently transformed into phenanthroindolizidines, 21 this work illustrates the versatility of these building blocks in the synthesis of both subfamilies of phenanthroizidine alkaloids. Our first strategy to build ring E of (R)-7-methoxycryptopleurine is based on a linear hydroformylation of the corresponding homoallylic amine intermediate. This approach has been widely used for a range of aminoalkenes in order to provide terminal aldehydes, which upon cyclization give enamine intermediates that can be transformed into different aza-heterocycles. 23 In this regard, we were particularly attracted by a rhodium catalyzed procedure where the syngas (CO/H 2 ) is conveniently substituted by formaldehyde, with excellent linear selectivity. 24 To minimize functional group manipulations and reduce the number of steps, we first tried the direct hydroformylation of sulfinamine 1, which can be prepared in six steps from commercially available starting materials 21 (Scheme 2). However, compound 1 proved to be unreactive under different conditions reported in the literature for the rhodium(I) catalyzed hydroformylation with formalin (37% aq. formaldehyde) or paraformaldehyde. We thus prepared the N-Boc protected homoallylic amine 2, which was submitted to rhodium(I) catalyzed hydroformylation with formalin, using two different phosphane ligands (BIBHEP and Ni-Xantphos). Under these conditions, the formation of the corresponding terminal aldehyde was followed by in-situ cyclization to furnish the protected enamine 3 in moderate yield (Scheme 2). Subsequent hydrogenation of the enamine moiety followed by acidic cleavage of the Boc group took place efficiently to obtain piperidine 4. Finally, the Pictet- Remarkably, after only one hour at room temperature, the use of commercially available second-generation Grubbs catalyst allowed the RCM reaction to proceed with almost quantitative yield. Catalytic hydrogenation of intermediate 8a was accomplished by using Adams`s catalyst to give compound 9a, 27 followed by acidic removal of the sulfinyl group and Pictet Spengler annulation. Phenanthroquinolizidine (S)-10 was obtained in 68% yield over four purification steps from compound 6. The same synthetic sequence was applied to obtain (R)-10 from ent-6 with similar efficiency in terms of isolated yields, and neither racemization nor significant enantioenrichment was observed by chiral HPLC analysis of the products (see SI). Having developed this protocol, we thus carried out the synthesis of target compound (S)-5 from compound ent-1. 21 Importantly, this synthetic protocol allowed the preparation of (S)-7-methoxycryptopleurine as a single isomer (>99:1 er by HPLC analysis), in 46% yield over four purification steps. The enantioenrichment of the target compound was simply achieved after conventional flash chromatography purifications of diastereomeric 8b
and 9b intermediates, according to chiral HPLC analysis (see SI). where paclitaxel -a potent anticancer agent-11 is inactive. In conclusion, we have developed two alternative procedures that allow the enantioselective preparation of 7-methoxycryptopleurine (5) 2-((2,3,6 ,7-Tetramethoxyphenanthren-9-yl)methyl)piperidine (4). A dry flask was charged with compound 3 (168 mg, 0.34 mmol), Pd(OH) 2 (20 % Pd on carbon powder with ca 60 % moisture, 98 mg, 0.09 mmol) and methanol (10 mL). A ballon of hydrogen gas was fitted to the equipment, and the flask was opened to vacuum for a few seconds, and then switched to the hydrogen ballon; this manipulation was repeated three times. The reaction mixture was allowed to stir at room temperature for 6 h. It was then filtered throught Celite, washing with EtOAc (3 x 15 mL), and the organic solution was concentrated to dryness under reduced pressure. To the obtained residue were added methanol (3.0 mL), trifluoroacetic acid (3.0 mL, 28.00 mmol) and CH 2 Cl 2 (3 mL) and the reaction mixture was stirred under argon at room temperature for 24 h. After the mixture was concentrated to dryness, a solution 2 M of NaOH (5 mL, 10 mmol) and CH 2 Cl 2 (10 mL) were added to the same flask. The aqueous phase was extracted with CH 2 Cl 2 (3 x 10 mL) and washed with brine (5 mL), dried over Na 2 SO 4 
(1S,R S )-N-Allyl-N-(tert-butylsulfinyl)-1-allyl-2-[phenanthren-9-yl]-ethylamine (7a).
To a solution of sulfinamine 6 25 
(2S,R S )-N-(tert-Butylsulfinyl)-2-(phenanthren-9-ylmethyl)piperidine (9a). A 25 mL
Schlenk tube was charged with compound 8a (149 mg, 0.40 mmol) and Adams' catalyst (16 mg, 0.04 mmol). Air was evacuated and replaced by an argon atmosphere before adding dry CH 2 Cl 2 (7.5 mL) and EtOAc (3 mL). The schlenk tube was connected to a hydrogen balloon through a three-ways valve and the reaction mixture was put under hydrogen atmosphere after 3 cycles of freeze-pump and thaw. 10 ). To a pressure tube were sequentially added compound 9a (94 mg, 0.25 mmol), trifluoroacetic acid (2 mL, 62 mmol) and 37% formalin (0.95 mL). The reaction mixture was put under argon atmosphere and heated to 90 ºC while stirring for 12 h in the dark.
After cooled to room temperature, the mixture was concentrated under vacuum and the residue was diluted with water (5mL) and 4 M solution of NaOH (2 mL). The aqueous phase was extracted with EtOAc (3 x 10 mL) and washed with brine (5 mL), dried over 
